Summit Therapeutics Stock Price, News & Analysis (LON:SUMM)

GBX 185.10 -2.40 (-1.28 %)
(As of 01/16/2018 06:52 AM ET)
Previous CloseGBX 187.50
Today's RangeGBX 185.10 - GBX 185.10
52-Week RangeGBX 140 - GBX 269.70
Volume71 shs
Average Volume12,010 shs
Market Capitalization£146.70 million
P/E Ratio-18,510.00
Dividend YieldN/A
BetaN/A

About Summit Therapeutics (LON:SUMM)

Summit Therapeutics logoSummit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD.

Receive SUMM News and Ratings via Email

Sign-up to receive the latest news and ratings for SUMM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolLON:SUMM
CUSIPN/A
Phone+44-1235-443939

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-18510
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSGBX (0.01)
Net IncomeN/A
Net Margins-102.61%
Return on Equity-72.51%
Return on Assets-15.82%

Miscellaneous

EmployeesN/A
Outstanding Shares70,630,000

Summit Therapeutics (LON:SUMM) Frequently Asked Questions

What is Summit Therapeutics' stock symbol?

Summit Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SUMM."

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics PLC (LON:SUMM) posted its quarterly earnings data on Wednesday, December, 6th. The company reported ($3.00) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($10.10) by $7.10. The firm had revenue of $1.73 million for the quarter. Summit Therapeutics had a negative return on equity of 72.51% and a negative net margin of 102.61%. View Summit Therapeutics' Earnings History.

Who are some of Summit Therapeutics' key competitors?

Who are Summit Therapeutics' key executives?

Summit Therapeutics' management team includes the folowing people:

  • Glyn Edwards, Chief Executive Officer, Executive Director (Age 59)
  • Erik Ostrowski, Chief Financial Officer (Age 42)
  • David Roblin, Chief Operating Officer, President - Research and Development
  • Ralf H. Rosskamp M.D., Chief Medical Officer (Age 63)
  • Frank Murdoch Armstrong, Non-Executive Chairman of the Board (Age 60)
  • Valerie L. Andrews, Non-Executive Director (Age 55)
  • Stephen J. Davies, Non-Executive Director (Age 64)
  • Barry J. Price Ph.D., Non-Executive Director (Age 71)
  • David Wurzer CPA, Non-Executive Director

How do I buy Summit Therapeutics stock?

Shares of Summit Therapeutics and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Summit Therapeutics' stock price today?

One share of Summit Therapeutics stock can currently be purchased for approximately GBX 185.10.

How big of a company is Summit Therapeutics?

Summit Therapeutics has a market capitalization of £146.70 million.

How can I contact Summit Therapeutics?

Summit Therapeutics' mailing address is 136A Eastern Avenue, Milton Park, ABINGDON, OX14 4SB, United Kingdom. The company can be reached via phone at +44-1235-443939.


MarketBeat Community Rating for Summit Therapeutics (SUMM)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  80 (Vote Outperform)
Underperform Votes:  159 (Vote Underperform)
Total Votes:  239
MarketBeat's community ratings are surveys of what our community members think about Summit Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Summit Therapeutics (LON:SUMM) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A

Summit Therapeutics (LON:SUMM) Consensus Price Target History

Price Target History for Summit Therapeutics (LON:SUMM)

Summit Therapeutics (LON:SUMM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
12/21/2017N+1 SingerReiterated RatingCorporateView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Summit Therapeutics (LON:SUMM) Earnings History and Estimates Chart

Earnings by Quarter for Summit Therapeutics (LON:SUMM)

Summit Therapeutics (LON SUMM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/6/2017Q3 2018GBX (10.10)GBX (3)GBX 173 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Summit Therapeutics (LON:SUMM) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Summit Therapeutics (LON:SUMM)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Summit Therapeutics (LON SUMM) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Summit Therapeutics (LON:SUMM)

Summit Therapeutics (LON SUMM) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/17/2015Valerie AndrewsInsiderBuy10,500GBX 145£15,225
(Data available from 1/1/2013 forward)

Headlines

Summit Therapeutics (LON SUMM) News Headlines

Source:
DateHeadline
Summit Therapeutics to Present at the Biotech ShowcaseSummit Therapeutics to Present at the Biotech Showcase
finance.yahoo.com - January 9 at 10:58 AM
Realm Therapeutics to Present at the 5th Annual Dermatology SummitRealm Therapeutics to Present at the 5th Annual Dermatology Summit
www.bizjournals.com - January 2 at 9:19 PM
Summit Therapeutics Buys Antibiotics Firm Discuva For GBP10 Million (ALLISS) - London South East (blog)Summit Therapeutics Buys Antibiotics Firm Discuva For GBP10 Million (ALLISS) - London South East (blog)
www.lse.co.uk - December 29 at 9:34 AM
Summit Therapeutics Plc breached its 50 day moving average in a Bullish Manner : SUMM-GB : December 28, 2017Summit Therapeutics Plc breached its 50 day moving average in a Bullish Manner : SUMM-GB : December 28, 2017
finance.yahoo.com - December 28 at 4:22 PM
Summit Enters Licence and Commercialisation Agreement with Eurofarma for Latin American Rights to Ridinilazole - London South East (blog)Summit Enters Licence and Commercialisation Agreement with Eurofarma for Latin American Rights to Ridinilazole - London South East (blog)
www.lse.co.uk - December 22 at 5:18 PM
UPDATE: Summit Therapeutics (SUMM) Agrees to Licence and Commercialisation Agreement With Eurofarma for Latin ... - StreetInsider.comUPDATE: Summit Therapeutics (SUMM) Agrees to Licence and Commercialisation Agreement With Eurofarma for Latin ... - StreetInsider.com
www.streetinsider.com - December 22 at 5:18 PM
Summit Therapeutics Signs Latin American License Deal With EurofarmaSummit Therapeutics Signs Latin American License Deal With Eurofarma
www.morningstar.co.uk - December 21 at 3:56 PM
Summit Therapeutics (SUMM) "Corporate" Rating Reaffirmed at N+1 SingerSummit Therapeutics' (SUMM) "Corporate" Rating Reaffirmed at N+1 Singer
www.americanbankingnews.com - December 21 at 3:06 PM
Summit Therapeutics Plc breached its 50 day moving average in a Bearish Manner : SUMM-GB : December 13, 2017Summit Therapeutics Plc breached its 50 day moving average in a Bearish Manner : SUMM-GB : December 13, 2017
finance.yahoo.com - December 13 at 11:31 AM
Summit Therapeutics Plc :SUMM-GB: Earnings Analysis: Q3, 2018 By the Numbers : December 11, 2017Summit Therapeutics Plc :SUMM-GB: Earnings Analysis: Q3, 2018 By the Numbers : December 11, 2017
finance.yahoo.com - December 12 at 11:49 AM
Summit Therapeutics Quarterly Loss Narrows On Higher RevenueSummit Therapeutics Quarterly Loss Narrows On Higher Revenue
www.morningstar.co.uk - December 7 at 11:39 AM
UK Stocks-Factors to watch on Dec 6UK Stocks-Factors to watch on Dec 6
www.reuters.com - December 7 at 11:39 AM
Summit Therapeutics (SUMM) Issues  Earnings Results, Beats Expectations By $7.10 EPSSummit Therapeutics (SUMM) Issues Earnings Results, Beats Expectations By $7.10 EPS
www.americanbankingnews.com - December 6 at 8:50 AM
Summit Therapeutics Plc breached its 50 day moving average in a Bullish Manner : SUMM-GB : November 27, 2017Summit Therapeutics Plc breached its 50 day moving average in a Bullish Manner : SUMM-GB : November 27, 2017
finance.yahoo.com - November 27 at 4:07 PM
Summit Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire (press release)Summit Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire (press release)
globenewswire.com - November 22 at 8:52 AM
Summit Therapeutics Reaches Midway Point Of PhaseOut DMD TrialSummit Therapeutics Reaches Midway Point Of PhaseOut DMD Trial
www.morningstar.co.uk - November 21 at 11:20 AM
SMMT To Report Data In Q1, PRTA Slumps, DBVTs Viaskin Value RealizedSMMT To Report Data In Q1, PRTA Slumps, DBVT's Viaskin Value Realized
www.rttnews.com - November 21 at 11:20 AM
 Reiterates "corporate" Rating for Summit Therapeutics PLC (SUMM) Reiterates "corporate" Rating for Summit Therapeutics PLC (SUMM)
www.americanbankingnews.com - November 19 at 1:40 PM
Summit Therapeutics plc : MiscellaneousSummit Therapeutics plc : Miscellaneous
finance.yahoo.com - November 16 at 8:41 AM
Summit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at Action DuchenneSummit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at Action Duchenne
finance.yahoo.com - November 9 at 2:14 PM
Summit Therapeutics Announces Revenue Sharing Agreement with Wellcome Trust - GlobeNewswire (press release)Summit Therapeutics Announces Revenue Sharing Agreement with Wellcome Trust - GlobeNewswire (press release)
globenewswire.com - November 6 at 7:23 AM
Summit Therapeutics plc : Grant of share optionsSummit Therapeutics plc : Grant of share options
finance.yahoo.com - October 25 at 2:34 PM
Summit Therapeutics plc : Block listing application - GlobeNewswire (press release)Summit Therapeutics plc : Block listing application - GlobeNewswire (press release)
globenewswire.com - October 23 at 7:49 AM
Summit Therapeutics plc : Block listing applicationSummit Therapeutics plc : Block listing application
finance.yahoo.com - October 23 at 7:49 AM
Summit Highlights Microbiome Preservation During Ridinilazole Treatment in Exploratory Phase 2 Clinical Trial at ID ... - GlobeNewswire (press release)Summit Highlights Microbiome Preservation During Ridinilazole Treatment in Exploratory Phase 2 Clinical Trial at ID ... - GlobeNewswire (press release)
globenewswire.com - October 11 at 8:35 PM
Summit Highlights DMD Biomarker Validation Data and Phase 2 Clinical Trial Baseline Characteristics in Presentations at 22nd WMS CongressSummit Highlights DMD Biomarker Validation Data and Phase 2 Clinical Trial Baseline Characteristics in Presentations at 22nd WMS Congress
finance.yahoo.com - October 4 at 10:35 AM
Summit Therapeutics plc: Holding(s) in CompanySummit Therapeutics plc: Holding(s) in Company
www.finanznachrichten.de - September 23 at 9:28 AM
Summit Therapeutics Says Underwriters Exercise Over-Allotment Option (ALLISS)Summit Therapeutics Says Underwriters Exercise Over-Allotment Option (ALLISS)
www.morningstar.co.uk - September 16 at 9:12 AM
Summit Therapeutics Plc breached its 50 day moving average in a Bearish Manner : SUMM-GB : September 15, 2017Summit Therapeutics Plc breached its 50 day moving average in a Bearish Manner : SUMM-GB : September 15, 2017
finance.yahoo.com - September 15 at 9:29 AM
Summit Therapeutics To Raise USD17.5 Million In ADS Offering On NASDAQSummit Therapeutics To Raise USD17.5 Million In ADS Offering On NASDAQ
www.morningstar.co.uk - September 14 at 10:49 AM
Summit Therapeutics Stock Gets Smoked After IPO PricingSummit Therapeutics Stock Gets Smoked After IPO Pricing
www.thestreet.com - September 14 at 10:49 AM
Summit Announces Underwritten Public Offering of 1,459,000 ADSs to Raise USD17.5 Million Before ExpensesSummit Announces Underwritten Public Offering of 1,459,000 ADSs to Raise USD17.5 Million Before Expenses
finance.yahoo.com - September 14 at 10:49 AM
MRNS Soars On Epilepsy Trial Data, SMMT Climbing Up, ACHN Takes A HitMRNS Soars On Epilepsy Trial Data, SMMT Climbing Up, ACHN Takes A Hit
www.rttnews.com - September 12 at 10:28 AM
BRIEF-Summit awarded BARDA contract worth up to $62 millionBRIEF-Summit awarded BARDA contract worth up to $62 million
www.reuters.com - September 12 at 10:28 AM
Summit Therapeutics Gets Contract To Support RidinilazoleSummit Therapeutics Gets Contract To Support Ridinilazole
www.morningstar.co.uk - September 12 at 10:28 AM
Summit Therapeutics Plc :SUMM-GB: Earnings Analysis: Q2, 2018 By the Numbers : September 12, 2017Summit Therapeutics Plc :SUMM-GB: Earnings Analysis: Q2, 2018 By the Numbers : September 12, 2017
finance.yahoo.com - September 12 at 10:28 AM
Summit Awarded BARDA Contract Worth Up to $62 Million to Support the Development of Ridinilazole for the Treatment of C. difficile InfectionSummit Awarded BARDA Contract Worth Up to $62 Million to Support the Development of Ridinilazole for the Treatment of C. difficile Infection
finance.yahoo.com - September 11 at 7:18 AM
Summit Therapeutics Awarded BARDA Contract Worth Up To $62M To Support Development of Ridinilazole for CDISummit Therapeutics Awarded BARDA Contract Worth Up To $62M To Support Development of Ridinilazole for CDI
finance.yahoo.com - September 11 at 7:18 AM
Summit Therapeutics Sees Positive Phase II Ridinilazole DataSummit Therapeutics Sees Positive Phase II Ridinilazole Data
www.morningstar.co.uk - September 6 at 8:50 AM
Ayretrade, Inc. (SUMM) Announces Positive Phase 2 Ridinilazole Top-Line Data for CDIAyretrade, Inc. (SUMM) Announces Positive Phase 2 Ridinilazole Top-Line Data for CDI
www.streetinsider.com - September 5 at 8:51 AM
Summit Therapeutics plc : Half-yearly report - GlobeNewswire (press release)Summit Therapeutics plc : Half-yearly report - GlobeNewswire (press release)
globenewswire.com - September 1 at 9:16 AM
An exciting pharma stock to consider alongside GlaxoSmithKline plcAn exciting pharma stock to consider alongside GlaxoSmithKline plc
www.fool.co.uk - August 31 at 10:36 AM
Summit Therapeutics Swings To Profit On DMD Milestone PaymentSummit Therapeutics Swings To Profit On DMD Milestone Payment
www.morningstar.co.uk - August 31 at 10:36 AM
Summit Therapeutics PLC (SUMM) Set to Announce Earnings on WednesdaySummit Therapeutics PLC (SUMM) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - August 30 at 1:38 AM
Summit Therapeutics to Present at the Canaccord Genuity Growth ConferenceSummit Therapeutics to Present at the Canaccord Genuity Growth Conference
finance.yahoo.com - August 3 at 7:41 AM
Summit Therapeutics plc : Total voting rightsSummit Therapeutics plc : Total voting rights
finance.yahoo.com - August 1 at 6:40 AM
Sarepta (SRPT) Q2 Loss Narrows, Ups Exondys 51 Sales View - NasdaqSarepta (SRPT) Q2 Loss Narrows, Ups Exondys 51 Sales View - Nasdaq
www.nasdaq.com - July 21 at 7:31 AM
Global Antibiotics Technologies, Markets, Competitors and Opportunities 2017-2022: The Quest for New Super DrugsGlobal Antibiotics Technologies, Markets, Competitors and Opportunities 2017-2022: The Quest for New Super Drugs
www.bizjournals.com - July 13 at 10:04 AM
Can Summit Therapeutics (SMMT) Run Higher on Strong Earnings ... - NasdaqCan Summit Therapeutics (SMMT) Run Higher on Strong Earnings ... - Nasdaq
www.nasdaq.com - July 4 at 3:40 PM
Summit Therapeutics Quarterly Loss Narrows On Milestone RevenueSummit Therapeutics Quarterly Loss Narrows On Milestone Revenue
www.morningstar.co.uk - June 15 at 10:13 PM

SEC Filings

Summit Therapeutics (LON:SUMM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Summit Therapeutics (LON SUMM) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.